High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease

Andrew G. Bostom, Lisa Yanek, Anne L. Hume, Charles B. Eaton, William McQuade, Marie Nadeau, Gayle Perrone, Paul F. Jacques, Jacob Selhub

Research output: Contribution to journalArticle

Abstract

Pharmacologic doses of folate, in the absence of clinical folate deficiency, can reduce plasma levels of the putatively atherothrombotic amino acid, homocysteine (H(e)). Data suggesting that H(e) may accumulate in experimental scurvy prompted us to explore the efficacy of high dose ascorbate supplementation as a H(e)-lowering treatment, in the absence of clinical ascorbate deficiency. A randomized, placebo-controlled trial of 12 weeks of high dose (4.5 g/day) ascorbate supplementation was completed by 44 patients with established coronary heart disease. No significant change in mean fasting total plasma H(e) levels was demonstrable despite a marked increase in mean fasting plasma Asorbate levels amongst those patients randomized to active treatment. Ascorbate supplementation to prevent the development of fasting hyperhomocysteinemia may only be relevant at scorbutic levels of plasma ascorbate.

Original languageEnglish (US)
Pages (from-to)267-270
Number of pages4
JournalAtherosclerosis
Volume111
Issue number2
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Homocysteine
Coronary Disease
Scurvy
Fasting
Folic Acid
Hyperhomocysteinemia
Randomized Controlled Trials
Placebos
Amino Acids
Therapeutics

Keywords

  • Homocysteine
  • Placebo-controlled trail
  • Vitamin C

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease. / Bostom, Andrew G.; Yanek, Lisa; Hume, Anne L.; Eaton, Charles B.; McQuade, William; Nadeau, Marie; Perrone, Gayle; Jacques, Paul F.; Selhub, Jacob.

In: Atherosclerosis, Vol. 111, No. 2, 1994, p. 267-270.

Research output: Contribution to journalArticle

Bostom, AG, Yanek, L, Hume, AL, Eaton, CB, McQuade, W, Nadeau, M, Perrone, G, Jacques, PF & Selhub, J 1994, 'High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease', Atherosclerosis, vol. 111, no. 2, pp. 267-270. https://doi.org/10.1016/0021-9150(94)90101-5
Bostom, Andrew G. ; Yanek, Lisa ; Hume, Anne L. ; Eaton, Charles B. ; McQuade, William ; Nadeau, Marie ; Perrone, Gayle ; Jacques, Paul F. ; Selhub, Jacob. / High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease. In: Atherosclerosis. 1994 ; Vol. 111, No. 2. pp. 267-270.
@article{4572ed07c6934ce19b0243d4ce393cc3,
title = "High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease",
abstract = "Pharmacologic doses of folate, in the absence of clinical folate deficiency, can reduce plasma levels of the putatively atherothrombotic amino acid, homocysteine (H(e)). Data suggesting that H(e) may accumulate in experimental scurvy prompted us to explore the efficacy of high dose ascorbate supplementation as a H(e)-lowering treatment, in the absence of clinical ascorbate deficiency. A randomized, placebo-controlled trial of 12 weeks of high dose (4.5 g/day) ascorbate supplementation was completed by 44 patients with established coronary heart disease. No significant change in mean fasting total plasma H(e) levels was demonstrable despite a marked increase in mean fasting plasma Asorbate levels amongst those patients randomized to active treatment. Ascorbate supplementation to prevent the development of fasting hyperhomocysteinemia may only be relevant at scorbutic levels of plasma ascorbate.",
keywords = "Homocysteine, Placebo-controlled trail, Vitamin C",
author = "Bostom, {Andrew G.} and Lisa Yanek and Hume, {Anne L.} and Eaton, {Charles B.} and William McQuade and Marie Nadeau and Gayle Perrone and Jacques, {Paul F.} and Jacob Selhub",
year = "1994",
doi = "10.1016/0021-9150(94)90101-5",
language = "English (US)",
volume = "111",
pages = "267--270",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - High dose ascorbate supplementation fails to affect plasma homocyst(e)ine levels in patients with coronary heart disease

AU - Bostom, Andrew G.

AU - Yanek, Lisa

AU - Hume, Anne L.

AU - Eaton, Charles B.

AU - McQuade, William

AU - Nadeau, Marie

AU - Perrone, Gayle

AU - Jacques, Paul F.

AU - Selhub, Jacob

PY - 1994

Y1 - 1994

N2 - Pharmacologic doses of folate, in the absence of clinical folate deficiency, can reduce plasma levels of the putatively atherothrombotic amino acid, homocysteine (H(e)). Data suggesting that H(e) may accumulate in experimental scurvy prompted us to explore the efficacy of high dose ascorbate supplementation as a H(e)-lowering treatment, in the absence of clinical ascorbate deficiency. A randomized, placebo-controlled trial of 12 weeks of high dose (4.5 g/day) ascorbate supplementation was completed by 44 patients with established coronary heart disease. No significant change in mean fasting total plasma H(e) levels was demonstrable despite a marked increase in mean fasting plasma Asorbate levels amongst those patients randomized to active treatment. Ascorbate supplementation to prevent the development of fasting hyperhomocysteinemia may only be relevant at scorbutic levels of plasma ascorbate.

AB - Pharmacologic doses of folate, in the absence of clinical folate deficiency, can reduce plasma levels of the putatively atherothrombotic amino acid, homocysteine (H(e)). Data suggesting that H(e) may accumulate in experimental scurvy prompted us to explore the efficacy of high dose ascorbate supplementation as a H(e)-lowering treatment, in the absence of clinical ascorbate deficiency. A randomized, placebo-controlled trial of 12 weeks of high dose (4.5 g/day) ascorbate supplementation was completed by 44 patients with established coronary heart disease. No significant change in mean fasting total plasma H(e) levels was demonstrable despite a marked increase in mean fasting plasma Asorbate levels amongst those patients randomized to active treatment. Ascorbate supplementation to prevent the development of fasting hyperhomocysteinemia may only be relevant at scorbutic levels of plasma ascorbate.

KW - Homocysteine

KW - Placebo-controlled trail

KW - Vitamin C

UR - http://www.scopus.com/inward/record.url?scp=0027940462&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027940462&partnerID=8YFLogxK

U2 - 10.1016/0021-9150(94)90101-5

DO - 10.1016/0021-9150(94)90101-5

M3 - Article

C2 - 7718029

AN - SCOPUS:0027940462

VL - 111

SP - 267

EP - 270

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -